Henry Schein (NASDAQ:HSIC) Issues Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Henry Schein (NASDAQ:HSIC) issued its quarterly earnings data on Tuesday. The company reported $1.27 EPS for the quarter, topping the consensus estimate of $1.24 by $0.03, FiscalAI reports. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. The business had revenue of $3.46 billion during the quarter, compared to analyst estimates of $3.37 billion. During the same period in the prior year, the business earned $1.10 EPS. The company’s revenue for the quarter was up 6.7% on a year-over-year basis. Henry Schein updated its FY 2026 guidance to 5.290-5.390 EPS.

Here are the key takeaways from Henry Schein’s conference call:

• Strong second-quarter performance: Global sales rose 6.7% to $3.5 billion, while non-GAAP operating income increased 10.5% and non-GAAP EPS grew 15.5% to $1.27, supported by 25 basis points of operating-margin expansion.
• Henry Schein raised its 2026 outlook, now expecting sales growth of 4.5%–5.5% and non-GAAP EPS of $5.29–$5.39, or 6%–8% growth. Management cited sustained sales momentum and stronger underlying performance, though the outlook excludes further remeasurement gains.
• The company remains on track for more than $200 million in operating-income improvements from its value-creation program, including a $125 million run-rate by year-end 2026; outsourcing, procurement consolidation, and pricing initiatives are beginning to contribute.
• Henry Schein One continued to post strong growth, with nearly 13,000 Dentrix Ascend and Dentally cloud customers and approximately 90% recurring revenue. AI-enabled clinical and practice-management tools are driving upgrades to higher-value packages and could increase customer retention and share of wallet.
• Growth was uneven across markets: U.S. dental merchandise and international businesses gained momentum, while U.S. dental equipment faced difficult comparisons and medical sales remained pressured by lower point-of-care diagnostic demand. Management expects U.S. equipment growth in the second half, but acknowledged that higher-margin specialty and technology mix benefits may be partly offset by equipment sales.

Henry Schein Price Performance

NASDAQ HSIC traded down $0.64 on Wednesday, reaching $88.47. The company had a trading volume of 324,735 shares, compared to its average volume of 1,397,061. The firm’s 50 day moving average price is $82.74 and its 200 day moving average price is $78.47. Henry Schein has a 12 month low of $61.94 and a 12 month high of $92.18. The stock has a market capitalization of $10.08 billion, a PE ratio of 26.73, a price-to-earnings-growth ratio of 1.66 and a beta of 0.80. The company has a quick ratio of 0.75, a current ratio of 1.36 and a debt-to-equity ratio of 0.59.

Analyst Ratings Changes

Several research firms recently weighed in on HSIC. Mizuho dropped their price target on Henry Schein from $88.00 to $82.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. Wall Street Zen raised shares of Henry Schein from a “hold” rating to a “buy” rating in a research report on Saturday. Weiss Ratings reiterated a “hold (c+)” rating on shares of Henry Schein in a report on Friday. BMO Capital Markets began coverage on Henry Schein in a research note on Wednesday, July 8th. They set a “market perform” rating and a $85.00 price objective for the company. Finally, Piper Sandler increased their price objective on shares of Henry Schein from $91.00 to $95.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Eight equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Henry Schein presently has a consensus rating of “Hold” and an average price target of $90.53.

Trending Headlines about Henry Schein

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Quarterly results exceeded expectations: Q2 revenue rose 6.7% year over year to $3.46 billion, above the $3.37 billion consensus estimate, while adjusted EPS of $1.27 topped expectations. EPS increased from $1.10 a year earlier. Henry Schein Reports Strong Second Quarter 2026 Financial Results and Raises FY2026 Guidance
• Positive Sentiment: Management raised its 2026 outlook: Henry Schein now expects non-GAAP EPS of $5.29–$5.39 and revenue of $13.8–$13.9 billion. The company also projects total sales growth of 4.5%–5.5% and adjusted EBITDA growth in the mid- to high-single digits, with the revenue outlook above the prior consensus estimate. Henry Schein Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Growth was broad-based: Global Distribution and Value-Added Services sales increased 6.6%, Specialty Products rose 8.7% and Technology sales grew 8.2%. Henry Schein also repurchased approximately 2.6 million shares for $200 million during the quarter, supporting per-share results. Henry Schein Q2 Revenue Rises 6.7%
• Positive Sentiment: Analyst confidence remains favorable: BTIG Research reaffirmed its Buy rating and set a $100 price target, implying roughly 12.5% upside from the reported reference price. Benzinga analyst rating report
• Neutral Sentiment: Momentum versus valuation: HSIC is trading near a 52-week high and above its 50-day and 200-day moving averages, indicating strong market momentum. However, its price-to-earnings ratio of about 26.8 suggests investors are already assigning a relatively healthy valuation to the improved outlook. Henry Schein Hits Fresh High
• Negative Sentiment: Insider activity is a cautionary signal: Company insiders reported six open-market sales and no purchases over the past six months. This does not necessarily indicate a change in fundamentals, but it may weigh on sentiment following the stock’s advance.

Insider Buying and Selling

In other Henry Schein news, Director William K. Daniel purchased 10,000 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was purchased at an average price of $69.19 per share, with a total value of $691,900.00. Following the acquisition, the director owned 20,000 shares in the company, valued at approximately $1,383,800. The trade was a 100.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.89% of the stock is owned by company insiders.

Institutional Investors Weigh In On Henry Schein

Hedge funds and other institutional investors have recently made changes to their positions in the company. Ameriprise Financial Inc. boosted its stake in shares of Henry Schein by 3,275.2% during the 2nd quarter. Ameriprise Financial Inc. now owns 2,266,858 shares of the company’s stock worth $165,594,000 after purchasing an additional 2,199,695 shares during the period. Bank of Montreal Can raised its holdings in shares of Henry Schein by 3,655.7% in the fourth quarter. Bank of Montreal Can now owns 2,144,773 shares of the company’s stock worth $162,102,000 after buying an additional 2,087,666 shares during the period. Southpoint Capital Advisors LP boosted its holdings in Henry Schein by 38.9% during the 4th quarter. Southpoint Capital Advisors LP now owns 2,500,000 shares of the company’s stock valued at $188,950,000 after acquiring an additional 700,000 shares during the period. Bank of America Corp DE increased its stake in Henry Schein by 204.2% in the second quarter. Bank of America Corp DE now owns 995,375 shares of the company’s stock worth $72,712,000 after purchasing an additional 668,182 shares during the period. Finally, Dimensional Fund Advisors LP lifted its position in shares of Henry Schein by 8.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,816,317 shares of the company’s stock worth $212,865,000 after purchasing an additional 220,149 shares during the last quarter. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.